{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:13:26Z","timestamp":1786119206159,"version":"build-2736575974"},"reference-count":113,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1097\/spc.0b013e3283090475","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T16:54:54Z","timestamp":1236272094000},"page":"204-210","source":"Crossref","is-referenced-by-count":9,"title":["New drugs in multiple myeloma"],"prefix":"10.1097","volume":"2","author":[{"given":"James R","family":"Berenson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ori","family":"Yellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210126","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.4065\/80.10.1371","article-title":"Multiple myeloma: diagnosis and treatment","volume":"80","author":"Rajkumar","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"R2-10-20210126","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"R3-10-20210126","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"key":"R4-10-20210126","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"R5-10-20210126","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","article-title":"High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA","volume":"106","author":"Blade","year":"2005","journal-title":"Blood"},{"key":"R6-10-20210126","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"R7-10-20210126","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma","volume":"127","author":"Jagannath","year":"2004","journal-title":"Br J Haematol"},{"key":"R8-10-20210126","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"R9-10-20210126","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2004-07-2911","article-title":"Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies","volume":"105","author":"Orlowski","year":"2005","journal-title":"Blood"},{"key":"R10-10-20210126","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00277-006-0220-3","article-title":"Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin","volume":"86","author":"Biehn","year":"2007","journal-title":"Ann Hematol"},{"key":"R11-10-20210126","doi-asserted-by":"crossref","first-page":"124a","DOI":"10.1182\/blood.V108.11.404.404","article-title":"The combination of pegylated liposomal doxorubicin and bortezomib significantly improves time to progression of patients with relapsed\/refractory multiple myeloma compared with bortezomib alone: results from a planned interim analysis of a randomized phase III study","volume":"108","author":"Orlowski","year":"2006","journal-title":"Blood"},{"key":"R12-10-20210126","first-page":"273","article-title":"A new model predicting at least a very good partial response in patients with multiple myeloma after 2 cycles of velcade-based therapy","volume":"91","author":"Friedman","year":"2006","journal-title":"Haematologica"},{"key":"R13-10-20210126","doi-asserted-by":"crossref","first-page":"378b","DOI":"10.1182\/blood.V106.11.5179.5179","article-title":"Combination therapy with velcade, doxil, and dexamethasone (VDD) for patients with relapsed\/refractory multiple myeloma (MM)","volume":"106","author":"Jakubowiak","year":"2005","journal-title":"Blood"},{"key":"R14-10-20210126","doi-asserted-by":"crossref","first-page":"659a","DOI":"10.1182\/blood.V104.11.2399.2399","article-title":"Bortezomib (Velcade) adriamycin thalidomide dexamethasone (VATD) as an effective regimen in patients with refractory or relapsed multiple myeloma (MM)","volume":"104","author":"Hollmig","year":"2004","journal-title":"Blood"},{"key":"R15-10-20210126","first-page":"281","article-title":"Low dose bortezomib, dexamethasone, thalidomide plus liposomal doxorubicin in relapsed and refractory myeloma","volume":"91","author":"Leoni","year":"2006","journal-title":"Haematologica"},{"key":"R16-10-20210126","first-page":"277","article-title":"Bortezomib (Velcade) in combination with liposomal doxorubicin (Doxil) and thalidomide is an active salvage regimen in patients with relapsed or refractory multiple myeloma: final results of a phase II trial","volume":"91","author":"Padmanabhan","year":"2006","journal-title":"Haematologica"},{"key":"R17-10-20210126","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"R18-10-20210126","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/cncr.23326","article-title":"Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide\/lenalidomide therapy","volume":"112","author":"Sonneveld","year":"2008","journal-title":"Cancer"},{"key":"R19-10-20210126","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1182\/blood-2006-04-019778","article-title":"Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1\/2 study","volume":"108","author":"Mateos","year":"2006","journal-title":"Blood"},{"key":"R20-10-20210126","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/blood.V110.11.76.76","article-title":"A phase 3 study comparing bortezomib\u2013melphalan\u2013prednisone (VMP) with melphalan\u2013prednisone (MP) in newly diagnosed multiple myeloma","volume":"110","author":"San Miguel","year":"2007","journal-title":"Blood"},{"key":"R21-10-20210126","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1182\/blood.V110.11.3602.3602","article-title":"Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients (pts) with newly diagnosed multiple myeloma (MM): an effective and well tolerated frontline regimen","volume":"110","author":"Berenson","year":"2007","journal-title":"Blood"},{"key":"R22-10-20210126","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1182\/blood.V98.3.805","article-title":"Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells","volume":"98","author":"Grad","year":"2001","journal-title":"Blood"},{"key":"R23-10-20210126","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0006-2952(01)00736-5","article-title":"Requirement for GSH in recycling of ascorbic acid in endothelial cells","volume":"62","author":"May","year":"2001","journal-title":"Biochem Pharmacol"},{"key":"R24-10-20210126","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/0006-2952(89)90499-1","article-title":"Glutathione and glutathione S-transferases in a human plasma cell line selected for resistance to melphalan","volume":"38","author":"Gupta","year":"1989","journal-title":"Biochem Pharmacol"},{"key":"R25-10-20210126","first-page":"995","article-title":"Development and characterization of a melphalan resistant human multiple myeloma cell line","volume":"51","author":"Bellamy","year":"1991","journal-title":"Cancer Res"},{"key":"R26-10-20210126","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1365-2141.2007.06675.x","article-title":"Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid","volume":"138","author":"Campbell","year":"2007","journal-title":"Br J Haematol"},{"key":"R27-10-20210126","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib","volume":"24","author":"Richardson","year":"2006","journal-title":"J Clin Oncol"},{"key":"R28-10-20210126","first-page":"111a","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy (PN) in the APEX trial","volume":"106","author":"San Miguel","year":"2005","journal-title":"Blood"},{"key":"R29-10-20210126","doi-asserted-by":"crossref","first-page":"423s","DOI":"10.1200\/jco.2006.24.18_suppl.7504","article-title":"Single-agent bortezomib in previously untreated multiple myeloma: results of a phase II multicenter study [Abstract 7504]","volume":"24","author":"Anderson","year":"2006","journal-title":"J Clin Oncol"},{"key":"R30-10-20210126","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1365-2141.2005.05519.x","article-title":"PAD combination therapy (PS-341\/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma","volume":"129","author":"Oakervee","year":"2005","journal-title":"Br J Haematol"},{"key":"R31-10-20210126","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"R32-10-20210126","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","article-title":"Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients","volume":"98","author":"Barlogie","year":"2001","journal-title":"Blood"},{"key":"R33-10-20210126","doi-asserted-by":"crossref","first-page":"897","DOI":"10.4065\/75.9.897","article-title":"Thalidomide in the treatment of relapsed multiple myeloma","volume":"75","author":"Rajkumar","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"R34-10-20210126","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0145-2126(03)00027-4","article-title":"An UK myeloma forum phase II study of thalidomide: long term follow-up and recommendations for treatment","volume":"27","author":"Schey","year":"2003","journal-title":"Leuk Res"},{"key":"R35-10-20210126","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/sj.thj.6200175","article-title":"Thalidomide in patients with advanced multiple myeloma: a study of 83 patients\u2013 report of the Intergroupe Francophone du Myelome (IFM)","volume":"3","author":"Yakoub-Agha","year":"2002","journal-title":"Hematol J"},{"key":"R36-10-20210126","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/sj.thj.6200403","article-title":"Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma","volume":"5","author":"Palumbo","year":"2004","journal-title":"Hematol J"},{"key":"R37-10-20210126","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/hon.738","article-title":"The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory\/relapsed multiple myeloma","volume":"22","author":"Hatjiharissi","year":"2004","journal-title":"Hematol Oncol"},{"key":"R38-10-20210126","first-page":"399","article-title":"Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma","volume":"86","author":"Palumbo","year":"2001","journal-title":"Haematologica"},{"key":"R39-10-20210126","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1600-0609.2005.00533.x","article-title":"Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant","volume":"75","author":"Palumbo","year":"2005","journal-title":"Eur J Haematol"},{"key":"R40-10-20210126","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/sj.leu.2403890","article-title":"The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory\/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL\/osteoprotegerin ratio","volume":"19","author":"Terpos","year":"2005","journal-title":"Leukemia"},{"key":"R41-10-20210126","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1600-0609.2007.00908.x","article-title":"Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma","volume":"79","author":"Murakami","year":"2007","journal-title":"Eur J Haematol"},{"key":"R42-10-20210126","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","article-title":"Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma","volume":"20","author":"Rajkumar","year":"2002","journal-title":"J Clin Oncol"},{"key":"R43-10-20210126","first-page":"826","article-title":"First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma","volume":"89","author":"Cavo","year":"2004","journal-title":"Haematologica"},{"key":"R44-10-20210126","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"key":"R45-10-20210126","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1182\/blood.V110.11.73.73","article-title":"Bortezomib (Velcade)-thalidomide-dexamethasone (VTD) vs thalidomide-dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM)","volume":"110","author":"Cavo","year":"2007","journal-title":"Blood"},{"key":"R46-10-20210126","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"key":"R47-10-20210126","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"R48-10-20210126","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"key":"R49-10-20210126","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1600-0609.2006.00774.x","article-title":"Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients","volume":"78","author":"Martino","year":"2007","journal-title":"Eur J Haematol"},{"key":"R50-10-20210126","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1200\/JCO.2006.05.6689","article-title":"Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring","volume":"24","author":"Mileshkin","year":"2006","journal-title":"J Clin Oncol"},{"key":"R51-10-20210126","doi-asserted-by":"crossref","first-page":"970a","DOI":"10.1182\/blood.V106.11.3475.3475","article-title":"Incidence and clinical course of peripheral neuropathy in patients receiving thalidomide for the treatment of multiple myeloma","volume":"106","author":"Naina","year":"2005","journal-title":"Blood"},{"key":"R53-10-20210126","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1160\/TH06-02-0080","article-title":"Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations","volume":"95","author":"Hussein","year":"2006","journal-title":"Thromb Haemost"},{"key":"R54-10-20210126","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.4065\/80.12.1549","article-title":"Thalidomide therapy and deep venous thrombosis in multiple myeloma","volume":"80","author":"Rajkumar","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"R55-10-20210126","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.4065\/80.12.1568","article-title":"The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma","volume":"80","author":"Baz","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"R56-10-20210126","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"R57-10-20210126","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","article-title":"A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma","volume":"108","author":"Richardson","year":"2006","journal-title":"Blood"},{"key":"R58-10-20210126","doi-asserted-by":"crossref","first-page":"149","DOI":"10.6004\/jnccn.2007.0015","article-title":"The emerging role of novel therapies for the treatment of relapsed myeloma","volume":"5","author":"Richardson","year":"2007","journal-title":"J Natl Compr Canc Netw"},{"key":"R59-10-20210126","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"R60-10-20210126","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"R61-10-20210126","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdl313","article-title":"Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy","volume":"17","author":"Baz","year":"2006","journal-title":"Ann Oncol"},{"key":"R62-10-20210126","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1365-2141.2007.06538.x","article-title":"Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients","volume":"137","author":"Morgan","year":"2007","journal-title":"Br J Haematol"},{"key":"R63-10-20210126","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"R64-10-20210126","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1182\/blood.V110.11.74.74","article-title":"A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group","volume":"110","author":"Rajkumar","year":"2007","journal-title":"Blood"},{"key":"R65-10-20210126","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1182\/blood.V110.11.2714.2714","article-title":"Lenalidomide, bortezomib, and dexamethasone (Rev\/Vel\/Dex) in patients with relapsed or relapsed\/refractory multiple myeloma (MM): preliminary results of a phase II study","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"R66-10-20210126","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/blood.V110.11.187.187","article-title":"Lenalidomide, bortezomib, and dexamethasone (Rev\/Vel\/Dex) as front-line therapy for patients with multiple myeloma (MM): preliminary results of a phase 1\/2 study","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"R67-10-20210126","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"The evolution of thalidomide and its IMiD derivatives as anticancer agents","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"R68-10-20210126","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","article-title":"Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"R69-10-20210126","doi-asserted-by":"crossref","first-page":"449a","DOI":"10.1182\/blood.V106.11.1565.1565","article-title":"A multicenter, single-arm, open-label study to evaluate the efficacy and safety of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma: preliminary results","volume":"106","author":"Richardson","year":"2005","journal-title":"Blood"},{"key":"R70-10-20210126","doi-asserted-by":"crossref","first-page":"427s","DOI":"10.1200\/jco.2006.24.18_suppl.7522","article-title":"Comparison of lenalidomide in combination with dexamethasone to dexamethasone alone in patients who have received prior thalidomide in relapsed or refractory multiple myeloma","volume":"24","author":"Wang","year":"2006","journal-title":"J Clin Oncol"},{"key":"R71-10-20210126","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMc053530","article-title":"Lenalidomide and venous thrombosis in multiple myeloma","volume":"354","author":"Knight","year":"2006","journal-title":"N Engl J Med"},{"key":"R72-10-20210126","doi-asserted-by":"crossref","first-page":"964a","DOI":"10.1182\/blood.V106.11.3455.3455","article-title":"High incidence of thrombotic events observed in patients receiving lenalidomide (L) _ dexamethasone (D) (LD) as first-line therapy for multiple myeloma (MM) without aspirin (ASA) prophylaxis","volume":"106","author":"Zonder","year":"2005","journal-title":"Blood"},{"key":"R73-10-20210126","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/j.1538-7836.2006.02059.x","article-title":"Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide","volume":"4","author":"Palumbo","year":"2006","journal-title":"J Thromb Haemost"},{"key":"R74-10-20210126","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMc053530","article-title":"Lenalidomide and venous thrombosis in multiple myeloma","volume":"354","author":"Rajkumar","year":"2006","journal-title":"N Engl J Med"},{"key":"R75-10-20210126","doi-asserted-by":"crossref","first-page":"423s","DOI":"10.1200\/jco.2006.24.18_suppl.7506","article-title":"Increased risk of thrombosis with lenalidomide in combination with dexamethasone and erythropoietin [Abstract 7506]","volume":"24","author":"Niesvizky","year":"2006","journal-title":"J Clin Oncol"},{"key":"R76-10-20210126","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/sj.leu.2402599","article-title":"Clinical activity of arsenic trioxide for the treatment of multiple myeloma","volume":"16","author":"Munshi","year":"2002","journal-title":"Leukemia"},{"key":"R77-10-20210126","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1365-2141.2004.04941.x","article-title":"Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma","volume":"125","author":"Hussein","year":"2004","journal-title":"Br J Haematol"},{"key":"R78-10-20210126","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/sj.leu.2403424","article-title":"A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients","volume":"18","author":"Rousselot","year":"2004","journal-title":"Leukemia"},{"key":"R79-10-20210126","first-page":"3658","article-title":"Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed\/refractory multiple myeloma","volume":"8","author":"Bahlis","year":"2002","journal-title":"Clin Cancer Res"},{"key":"R80-10-20210126","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1182\/blood.V106.11.5135.5135","article-title":"Treatment with arsenic trioxide, ascorbic acid and dexamethasone in advanced myeloma patients: preliminary findings of a multicenter, phase II study","volume":"106","author":"Wu","year":"2005","journal-title":"Blood"},{"key":"R81-10-20210126","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2141.2006.06280.x","article-title":"Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study","volume":"135","author":"Berenson","year":"2006","journal-title":"Br J Haematol"},{"key":"R82-10-20210126","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1158\/1078-0432.CCR-06-1812","article-title":"A phase I\/II study of arsenic trioxide\/bortezomib\/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma","volume":"13","author":"Berenson","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R83-10-20210126","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3816\/CLM.2006.n.058","article-title":"Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy","volume":"7","author":"Berenson","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"R84-10-20210126","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/j.1540-8159.1999.tb06826.x","article-title":"Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemic patient","volume":"22","author":"Huang","year":"1999","journal-title":"Pacing Clin Electrophysiol"},{"key":"R85-10-20210126","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1182\/blood.V98.2.266","article-title":"Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide","volume":"98","author":"Westervelt","year":"2001","journal-title":"Blood"},{"key":"R87-10-20210126","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2007-08-105601","article-title":"Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma","volume":"111","author":"Chauhan","year":"2008","journal-title":"Blood"},{"key":"R88-10-20210126","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood.V110.11.409.409","article-title":"Safety and Antitumor Efficacy of the Proteasome Inhibitor Carfilzomib (PR-171) Dosed for Five Consecutive Days in Hematologic Malignancies: Phase 1 Results","volume":"110","author":"Orlowski","year":"2007","journal-title":"Blood"},{"key":"R89-10-20210126","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood.V110.11.411.411","article-title":"Phase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies","volume":"110","author":"Alsina","year":"2007","journal-title":"Blood"},{"key":"R90-10-20210126","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood-2003-01-0233","article-title":"NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma","volume":"102","author":"Catley","year":"2003","journal-title":"Blood"},{"key":"R91-10-20210126","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood-2006-04-016055","article-title":"Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells","volume":"108","author":"Catley","year":"2006","journal-title":"Blood"},{"key":"R92-10-20210126","doi-asserted-by":"crossref","first-page":"5781","DOI":"10.1158\/0008-5472.CAN-05-4186","article-title":"The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance","volume":"66","author":"Maiso","year":"2006","journal-title":"Cancer Res"},{"key":"R93-10-20210126","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1073\/pnas.0503221102","article-title":"Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma","volume":"102","author":"Hideshima","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R94-10-20210126","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/10428190701817258","article-title":"Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma","volume":"49","author":"Richardson","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"R95-10-20210126","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1182\/blood.V110.11.1172.1172","article-title":"Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in combination with bortezomib in patients with advanced multiple myeloma","volume":"110","author":"Weber","year":"2007","journal-title":"Blood"},{"key":"R96-10-20210126","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1182\/blood.V110.11.1168.1168","article-title":"Phase I trial of suberoylanilide hydroxamic acid (SAHA) + bortezomib (Bort) in relapsed multiple myeloma (MM) patients (pts)","volume":"110","author":"Badros","year":"2007","journal-title":"Blood"},{"key":"R97-10-20210126","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2005-03-1158","article-title":"Antimyeloma activity of heat shock protein-90 inhibition","volume":"107","author":"Mitsiades","year":"2006","journal-title":"Blood"},{"key":"R98-10-20210126","doi-asserted-by":"crossref","first-page":"14374","DOI":"10.1073\/pnas.202445099","article-title":"Molecular sequelae of proteasome inhibition in human multiple myeloma cells","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R99-10-20210126","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1080\/10428190500472123","article-title":"Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma","volume":"47","author":"Duus","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"R100-10-20210126","doi-asserted-by":"crossref","first-page":"17408","DOI":"10.1073\/pnas.0608372103","article-title":"Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anticancer agent directed against Hsp90","volume":"103","author":"Sydor","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R101-10-20210126","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood-2006-05-024372","article-title":"STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90 alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival","volume":"109","author":"Chatterjee","year":"2007","journal-title":"Blood"},{"key":"R102-10-20210126","doi-asserted-by":"crossref","first-page":"6826","DOI":"10.1158\/1078-0432.CCR-06-1331","article-title":"Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma","volume":"12","author":"Francis","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R103-10-20210126","doi-asserted-by":"crossref","first-page":"109a","DOI":"10.1182\/blood.V106.11.361.361","article-title":"Safety and activity of KOS-953 in patients with relapsed refractory multiple myeloma (MM): interim results of a phase I trial","volume":"106","author":"Richardson","year":"2005","journal-title":"Blood"},{"key":"R104-10-20210126","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood.V110.11.1165.1165","article-title":"Tanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): confirmation of the recommended dose using a novel formulation","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"R105-10-20210126","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1038\/sj.onc.1204833","article-title":"Biologic sequelae of interleukin-6 induced PI3-K\/Akt signaling in multiple myeloma","volume":"20","author":"Hideshima","year":"2001","journal-title":"Oncogene"},{"key":"R106-10-20210126","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1182\/blood.V98.9.2853","article-title":"The AKT kinase is activated in multiple myeloma tumor cells","volume":"98","author":"Hsu","year":"2001","journal-title":"Blood"},{"key":"R107-10-20210126","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/sj.onc.1205194","article-title":"Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses","volume":"21","author":"Hsu","year":"2002","journal-title":"Oncogene"},{"key":"R108-10-20210126","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1038\/sj.onc.1205664","article-title":"Activation of NF-kappaB and upregulation of intracellular antiapoptotic proteins via the IGF-1\/Akt signaling in human multiple myeloma cells: therapeutic implications","volume":"21","author":"Mitsiades","year":"2002","journal-title":"Oncogene"},{"key":"R109-10-20210126","first-page":"3876","article-title":"Cytokines modulate telomerase activity in a human multiple myeloma cell line","volume":"62","author":"Akiyama","year":"2002","journal-title":"Cancer Res"},{"key":"R110-10-20210126","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/blood-2006-10-052845","article-title":"JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells","volume":"110","author":"Kiziltepe","year":"2007","journal-title":"Blood"},{"key":"R111-10-20210126","first-page":"155","article-title":"A multicenter phase I\/II trial of perifosine (KRX-0401) + bortezomib in relapsed and refractory multiple myeloma patients treated with bortezomib: Preliminary results","volume":"92","author":"Richardson","year":"2007","journal-title":"Haematologica"},{"key":"R112-10-20210126","first-page":"155","article-title":"Perifosine (KRX-0401) plus low dose dexamethasone is active in patients with relapsed and refractory multiple myeloma (MM): perifosine MM investigator group phase II multicenter study update","volume":"92","author":"Richardson","year":"2007","journal-title":"Haematologica"},{"key":"R113-10-20210126","first-page":"154","article-title":"A multicenter phase I trial of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma: preliminary results. Multiple myeloma research consortium (MMRC) trial","volume":"92","author":"Jakubowiak","year":"2007","journal-title":"Haematologica"},{"key":"R114-10-20210126","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1182\/blood-2004-03-1153","article-title":"In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model","volume":"104","author":"Frost","year":"2004","journal-title":"Blood"},{"key":"R115-10-20210126","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1182\/blood-2004-06-2281","article-title":"Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma","volume":"104","author":"Raje","year":"2004","journal-title":"Blood"}],"container-title":["Current Opinion in Supportive & Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/SPC.0b013e3283090475","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:40:39Z","timestamp":1786038039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01263393-200809000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":113,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0b013e3283090475","relation":{},"ISSN":["1751-4258"],"issn-type":[{"value":"1751-4258","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}